Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
Carrascosa A, Audí L, Esteban C, Fernández-Cancio M, Andaluz P, Gussinyé M, Clemente M, Yeste D, Albisu MA. Carrascosa A, et al. Among authors: esteban c. J Clin Endocrinol Metab. 2008 Jan;93(1):147-53. doi: 10.1210/jc.2007-1182. Epub 2007 Oct 9. J Clin Endocrinol Metab. 2008. PMID: 17925340
Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA.
Audí L, Esteban C, Carrascosa A, Espadero R, Pérez-Arroyo A, Arjona R, Clemente M, Wollmann H, Fryklund L, Parodi LA; Spanish SGA Study Group. Audí L, et al. Among authors: esteban c. J Clin Endocrinol Metab. 2006 Dec;91(12):5038-43. doi: 10.1210/jc.2006-0828. Epub 2006 Sep 26. J Clin Endocrinol Metab. 2006. PMID: 17003087
The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
Carrascosa A, Audí L, Fernández-Cancio M, Esteban C, Andaluz P, Vilaró E, Clemente M, Yeste D, Albisu MA, Gussinyé M. Carrascosa A, et al. Among authors: esteban c. J Clin Endocrinol Metab. 2008 Mar;93(3):764-70. doi: 10.1210/jc.2007-2180. Epub 2007 Dec 26. J Clin Endocrinol Metab. 2008. PMID: 18160465
The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
Audí L, Carrascosa A, Esteban C, Fernández-Cancio M, Andaluz P, Yeste D, Espadero R, Granada ML, Wollmann H, Fryklund L; Spanish SGA Study Group. Audí L, et al. Among authors: esteban c. J Clin Endocrinol Metab. 2008 Jul;93(7):2709-15. doi: 10.1210/jc.2008-0150. Epub 2008 Apr 29. J Clin Endocrinol Metab. 2008. PMID: 18445665 Clinical Trial.
The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients.
Carrascosa A, Esteban C, Espadero R, Fernández-Cancio M, Andaluz P, Clemente M, Audí L, Wollmann H, Fryklund L, Parodi L; Spanish SGA Study Group. Carrascosa A, et al. Among authors: esteban c. J Clin Endocrinol Metab. 2006 Sep;91(9):3281-6. doi: 10.1210/jc.2006-0685. Epub 2006 Jun 27. J Clin Endocrinol Metab. 2006. PMID: 16804042 Clinical Trial.
331 results